Temporal muscle thickness as an independent prognostic imaging marker in newly diagnosed glioblastoma patients: A validation study
Open Access
- 30 March 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 4 (1) , vdac038
Abstract
Previous studies have recognized temporal muscle thickness (TMT) as a prognostic marker in glioblastoma, but clinical implementation is hampered due to studies’ heterogeneity and lack of established cutoff values. The aim of this study was to assess the validity of recent proposed sex-specific TMT cutoff values in a real-world population of genotyped primary glioblastoma patients. We measured TMT in preoperative MR images of 328 patients. Sex-specific TMT cutoff values were used to divide patients into “at risk of sarcopenia” or “normal muscle status”. Kaplan-Meier analyses and stepwise multivariate Cox-Regression analyses were used to assess the association with overall survival (OS) and progression-free survival (PFS). The association with occurrence of complications and discontinuation of glioblastoma treatment was investigated using odds ratios (OR). Patients at risk of sarcopenia had a significantly higher risk of progression and death than patients with normal muscle status, which remained significant in the multivariate analyses (OS HR = 1.437; 95%CI: 1.046–1.973; P = .025 and PFS HR = 1.453; 95%CI: 1.037–2.036; P = .030). Patients at risk of sarcopenia also had a significantly higher risk of early discontinuation of treatment (OR = 2.45; 95%CI: 1.011–5.952; P = .042) and a significantly lower chance of receiving second-line treatment (OR = 0.23; 95%CI: 0.09–0.60; P = .001). There was no association with the occurrence of complications. Our study confirms external validity of the use of proposed sex-specific TMT cutoff values as an independent prognostic marker in newly diagnosed glioblastoma patients. This simple, noninvasive marker could improve patient counseling and aid in treatment decision processes or trial stratification.Keywords
This publication has 27 references indexed in Scilit:
- Short-Course Radiation plus Temozolomide in Elderly Patients with GlioblastomaNew England Journal of Medicine, 2017
- Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastasesEuropean Radiology, 2017
- Validation of the SarQoL®, a specific health‐related quality of life questionnaire for SarcopeniaJournal of Cachexia, Sarcopenia and Muscle, 2016
- Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic reviewEuropean Journal of Cancer, 2016
- Moving beyond Karnofsky and ECOG Performance Status Assessments with New TechnologiesJournal of Oncology, 2016
- Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung CancerJournal of Thoracic Oncology, 2015
- A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial resultsTrials, 2015
- Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine TreatmentClinical Cancer Research, 2009
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3The Lancet Oncology, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005